Liu Xiaolei, Zhang Zihuan, Huang Jia, Tan Haidong, Yang Zhiying
Department of Hepatobiliary Surgery, China-Japan Friendship Hospital, Beijing, People's Republic of China.
Cancer Manag Res. 2021 Nov 3;13:8273-8279. doi: 10.2147/CMAR.S334171. eCollection 2021.
Hepatic epithelioid hemangioendothelioma (HEH) is a rare tumor type. No effective medicine or standard treatment for HEH has been established.
From March 2014 to April 2021, 62 patients with pathologically diagnosed HEH were observed regularly, and interferon-alpha 2b (IFN-a 2b) was administered to patients with progressive disease or reoccurrence. Adverse events (AEs) were assessed and recorded, and a tumor assessment scan was performed every 3 months.
A total of 42 patients with HEH received IFN-a 2b treatment in this study. No severe (grade ≥3) AEs were reported in the group overall. The most common treatment-related AEs in patients receiving IFN-a 2b were fever (50.0%) and fatigue (21.4%). Partial response and complete response were achieved in 20 patients (47.6%) and 2 patients (4.8%), respectively, and the objective response rate was 52.4%. Stable disease was observed in 12 patients (28.6%), and the disease control rate was 81.0%. Progressive disease was observed in 8 patients (19.0%). The 1-, 3-, and 5-year progression-free survival rates were 81.0%, 69.2%, and 62.3%, respectively. Only 1 patient died as a result of disease progression during the study. The 1-, 3-, and 5-year overall survival rates were 100%, 97.2%, and 97.2%, respectively.
IFN-a 2b is a safe and effective treatment for patients with HEH. The encouraging results with IFN-a 2b use make it a promising option for patients who have other types of epithelioid hemangioendothelioma; additional clinical trials are needed.
肝上皮样血管内皮瘤（HEH）是一种罕见的肿瘤类型。目前尚未确立针对HEH的有效药物或标准治疗方法。
2014年3月至2021年4月，对62例经病理诊断为HEH的患者进行定期观察，对疾病进展或复发的患者给予α-2b干扰素（IFN-α 2b）治疗。评估并记录不良事件（AE），每3个月进行一次肿瘤评估扫描。
本研究共有42例HEH患者接受了IFN-α 2b治疗。该组总体未报告严重（≥3级）AE。接受IFN-α 2b治疗的患者中最常见的与治疗相关的AE为发热（50.0%）和疲劳（21.4%）。分别有20例患者（47.6%）和2例患者（4.8%）达到部分缓解和完全缓解，客观缓解率为52.4%。12例患者（28.6%）病情稳定，疾病控制率为81.0%。8例患者（19.0%）疾病进展。1年、3年和5年无进展生存率分别为81.0%、69.2%和62.3%。研究期间仅1例患者因疾病进展死亡。1年、3年和5年总生存率分别为100%、97.2%和97.2%。
IFN-α 2b对HEH患者是一种安全有效的治疗方法。使用IFN-α 2b取得的令人鼓舞的结果使其成为患有其他类型上皮样血管内皮瘤患者的一个有前景的选择；需要进行更多的临床试验。
